Trials / Completed
CompletedNCT01069133
Study of Rifaximin in Minimal Hepatic Encephalopathy
Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy,Diffusion Tensor Imaging Microbiome and Metabolome: a Prospective Trial
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center · Federal
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | 550mg BID open-label |
| DRUG | rifaximin | 550mg PO BID |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2012-05-01
- Completion
- 2012-12-01
- First posted
- 2010-02-17
- Last updated
- 2012-12-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01069133. Inclusion in this directory is not an endorsement.